19.4 C
New York
Wednesday, June 29, 2022

Selected Notes From Analysts On Teladoc Health Inc. (TDOC) Stock

Teladoc Health Inc. (NYSE: TDOC) has lost more than 60% of its value in the previous 12 months. This is because of investors’ unfavorable expectations in the face of a reduction in the impact of pandemic variables. Experts, on the other hand, believe Teladoc’s expansion may restart.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Analysts at Piper Sandler, for instance, reiterated their buy rating for Teladoc Health shares on Friday, May 13, and even boosted their target price from $41 to $42 significantly.

Wall Street’s top investment companies, on the other hand, cut their ratings and financial estimates for Teladoc Health in April-May 2022. Piper Sandler analysts, on the other hand, had many talks with Teladoc Health officials, examined the current market for consumer-oriented medical services, and decided to keep the current rating while raising the target price.

During the pandemic, when outpatient clinics were closed to accommodate non-COVID-19 patients, Teladoc Health was one of the fastest-growing tickers. Telemedicine has become the sole means to acquire medical advice in many circumstances. The firm swiftly boosted the number of applicants and signed new contracts with employers throughout the epidemic quarters.

Obviously, this pleased investors who backed the rise in Teladoc Health stock prices. Stocks are currently trading 80 percent below their 52-week highs due to the diminishing impact of the epidemic and decreased management forecasts for revenue and profitability.

Teladoc Health is unlikely to be able to replicate its explosive expansion from 2020 in the near future. The company’s long-term growth drivers, on the other hand, are unrelated to the epidemic. The anticipated lack of physicians and nurses, for example, might result in an increase in remote consultations, particularly from inhabitants of small towns or distant villages.

Furthermore, as the population of high-income nations ages, more frequent referrals to mental health counseling and assistance in caring for inactive patients will be required. As a result, we may conclude that the pandemic was a bright moment in Teladoc Health’s history, but not exactly the pinnacle of the company’s growth. Most likely, Teladoc is only at the start of a lengthy journey, but it is already a market leader with a significant edge.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles




Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam